BiomeSense and Simple Mills top Chicago's recent funding news

BiomeSense and Simple Mills top Chicago's recent funding newsPhoto: Facebook
Hoodline
Published on October 15, 2019

Chicago-based biotechnology and life science company BiomeSense has secured $2 million in seed funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced September 24 and led by BioX Clan.

According to its Crunchbase profile, "BiomeSense is revolutionizing human microbiome research by developing novel technologies to enable investigators to collect, store, and analyze the daily microbiome profiles of clinical trial participants in a low-cost, scalable way. By enabling daily profiling, the platform allows investigators the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, dramatically increasing the research discovery potential."

The two-year-old startup also raised a seed round earlier this year.

The round brings total funding raised by Chicago companies in biotechnology over the past month to $91 million, an increase of $78 million from the month before. The local biotechnology industry has produced 13 funding rounds over the past year, yielding a total of $384 million in venture funding.

In other local funding news, manufacturing and food processing company Simple Mills announced a private equity funding round on October 7, financed by Vestar Capital Partners.

According to Crunchbase, "Simple MIlls is a portfolio brand transforming the center store with delicious baking mixes, frostings, cookies, and crackers. Our products are made with only simple, nutritious ingredients that work harder for your body and nothing artificial, ever. And best of all, they taste great so there's no compromise!"

Founded in 2013, the company has raised four previous rounds, including a $2.9 million round earlier this year.


This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.